Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for
tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who
have untreated or relapsed Waldenstrom's macroglobulinemia.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI)